Cell proliferation in the striatum during postnatal development: preferential distribution in subregions of the ventral striatum.
Cortico-ventral basal ganglia circuitry is associated with a variety of mental health disorders including obsessive-compulsive disorder and drug addiction, disorders that emerge during childhood through young adulthood, a period in which the cortex and striatum continue to development. Moreover, cell proliferation, which is associated with development and plasticity, also continues in the cortex and striatum through adulthood. Given the implication of cortico-basal ganglia circuitry in diseases emerging during postnatal development, we studied cell proliferation at different ages in striatal regions associated with specific frontal cortical areas. The results show cell proliferation throughout the striatum at all postnatal ages. The majority of the new cells were immunoreactive for NG2 chondroitin sulfate, a marker for specific progenitor cells, but not for NeuN, a neuronal marker. Although neurogenesis was not observed, approximately 30% of the new cells appeared to be paired with a neuron. There was a significantly higher degree of cell proliferation during the first postnatal year compared to other striatal regions. Finally, throughout the juvenile years, the ventral striatal areas receiving input from the ventral, medial prefrontal cortex and orbital prefrontal cortex have significantly more new cells compared to other striatal regions. Integrity of the ventral striatum is critical for the development of goal-directed behaviors. The high number of new cells in the ventral striatum during postnatal development may be particularly important for the refinement of the cortico-striatal network, and in the formation of neural ensembles fundamental to learning during behavioral development.
Stopczynski
Rachelle E
RE
University of Pittsburgh/Carnegie Mellon University Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Poloskey
Stacey L
SL
Haber
Suzanne N
SN
D000367:Age Factors; D000818:Animals; D000941:Antigens / Q000378:metabolism; D001479:Basal Ganglia / Q000166:cytology* / Q000254:growth & development / Q000378:metabolism; D001973:Bromodeoxyuridine / Q000378:metabolism; D049109:Cell Proliferation; D003342:Corpus Striatum / Q000166:cytology* / Q000254:growth & development / Q000378:metabolism; D007150:Immunohistochemistry; D008252:Macaca fascicularis; D008297:Male; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009434:Neural Pathways / Q000166:cytology / Q000254:growth & development / Q000378:metabolism; D009457:Neuroglia / Q000166:cytology / Q000378:metabolism; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D017397:Prefrontal Cortex / Q000166:cytology / Q000254:growth & development / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism; D000099216:Chondroitin Sulfate Proteoglycan 4
D000941:Antigens; D001973:Bromodeoxyuridine; D009419:Nerve Tissue Proteins; D011509:Proteoglycans; D000099216:Chondroitin Sulfate Proteoglycan 4